Clinical Trial Update: Phase I/II Trial to Evaluate Safety, Tolerability and Pharmacokinetic Profile of HM61713 in NSCLC Patients [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II trial assessing safety, tolerability, and pharmacokinetics of HM61713 in non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• HM61713

Snippet

Sponsor: Hanmi Pharmaceutical Company Limited | Conditions: Non Small Cell Lung Cancer | Phase 1, Phase 2 | Status: COMPLETED